Please assess the completion status of the following clinical trial:

Trial Title: Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged 18 to 60 years, inclusive.~* Body mass index 19.0 to 35.0 kg/m2~* Intact normal skin without potentially obscuring tattoos, pigmentation, or lesions on the upper back in the area intended for infusion~* Free from any clinically significant abnormality on the basis of medical/medication history or physical examination~* Vital signs and clinical laboratory parameters within normal range or, if outside normal range, deemed not clinically significant~* Negative urine drug and alcohol screens.~Exclusion Criteria:~* Upper back pathology that could interfere with study outcome.~* History of congestive heart failure, known coronary heart disease, active or recent pulmonary disease, or renal insufficiency.~* Rales on lung auscultation.~* Known allergy to hyaluronidase or any other ingredient in the formulation of hylenex recombinant~* Treatment with furosemide, benzodiazepines, or phenytoin.~* Pregnancy or breastfeeding.~* Exposure to any experimental drug within 30 days prior to study admission, or previous participation in this study.~* Any other reason which, in the investigator's opinion, would prevent the safe participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- 24 ga catheter, dose flush, single-step rate scheme (Type: EXPERIMENTAL): Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
- 24 ga catheter, no dose flush, single-step rate scheme (Type: EXPERIMENTAL): Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
- 24 ga catheter, dose flush, up-titrated rate scheme (Type: EXPERIMENTAL): Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
- 24 ga catheter, no dose flush, up-titrated rate scheme (Type: EXPERIMENTAL): Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
- 25 ga needle, dose flush, single-step rate scheme (Type: EXPERIMENTAL): Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
- 25 ga needle, no dose flush, single-step rate scheme (Type: EXPERIMENTAL): Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
- 25 ga needle, dose flush, up-titrated rate scheme (Type: EXPERIMENTAL): Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
- 25 ga needle, no dose flush, up-titrated rate scheme (Type: EXPERIMENTAL): Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy